Datopotamab Deruxtecan Plus Pembrolizumab With and Without Platinum-Based Chemotherapy Demonstrates Promise in Advanced Non-Small Cell Lung Cancer
According to results from the TROPION-Lung02 study, datopotamab deruxtecan (Dato-DXd) plus pembrolizumab both with and without the addition of platinum-based chemotherapy demonstrated promising durability and safety among patients with advanced non-small cell lung cancer (NSCLC).
These data were first presented by Benjamin Long, MD, Johns Hopkins University School of Medicine, Baltimore, Maryland, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
In this study, researchers enrolled 96 patients into 6 cohorts to receive Dato-DXd (4 or 6 mg/kg) plus pembrolizumab (200 mg) either alone (doublet arm; n = 42) or in combination (triplet arm; n = 54) with platinum-based chemotherapy (75 mg/m2 of cisplatin or AUC 5 carboplatin) once every 3 weeks. Primary end points included safety and tolerability. Key secondary end points included objective response rate (ORR), disease control rate, duration of response, and progression-free survival (PFS).
At analysis, treatment was ongoing in 29% of patients in the doublet arm and 15% of patients in the triplet arm. The most common adverse events included stomatitis and nausea (mostly grade 1/2). Serious treatment-related adverse events occurred in 12% and 22% of patients, respectively. No treatment-related deaths were reported. The confirmed ORR was 55% in the doublet arm and 56% in the triplet arm and disease control rates were 88% and 89%, respectively. The median duration of response was 20.1 months in the doublet arm and 13.7 months in the triplet arm and median PFS was 11.2 months and 6.8 months, respectively.
“In this largest data set to date evaluating an [antibody drug conjugate] combined with an anti-PD-1/L1 agent in the [first-line] setting, the combination of Dato-DXd plus pembro[lizumab] treatment both with and without [platinum chemotherapy] elicited durable antitumor activity in [patients] with aNSCLC,” concluded Dr Levy et al.
Source:
Levy B, Paz-Ares L, Lin CC, et al. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC). Presented at 2025 ASCO Annual Meeting. May 30-June 3, 2025; Chicago, IL. Abstract 8501
